Waystar initiated at Buy at Barclays and RBC, upside potential up to 25%

Several investment firms initiated research coverage on Waystar Holding (WAY), roughly a month after the cloud-based software solution provider made its debut via an initial public offering (IPO).

Among those firms was Barclays, which started its coverage on WAY shares with an Overweight rating and a price target of $24.

“WAY is aligned with a number of mission critical end markets within health tech, insulating the company from the sector’s typical volatility,” analysts at Barclays said in a note.

“We believe this affords WAY a business model durability rarely seen in the sector, meriting a premium multiple,” they said, adding that WAY’s end-market should see high single-digit transaction volume growth and low double-digit wallet growth.

Similarly, RBC Capital Markets also started coverage on WAY with an Outperform rating and a price target of $27, implying an upside potential of 25% from current levels.

The investment bank views Waystar as an industry leader in the revenue cycle software sector, with its modular offerings utilizing data and technology to improve the billing and collection functions for its healthcare provider clients.

“We remain very positive on the broader rev cycle macro backdrop, which coupled with cross-selling and market share gains should enable WAY to sustain ~10% organic revenue growth and 40% + EBITDA margins over the next 3+ years,” analysts at RBC Capital Markets wrote.

Key factors that make WAY stand out in its sector include the breadth of its platform, innovation, and strong client support, analysts added.

WAY stock is currently covered by 10 analysts, all of which have rated the stock at Buy.